| 9.22 -0.24 (-2.54%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.92  |
1-year : | 14.28 |
| Resists | First : | 11.06 |
Second : | 12.22 |
| Pivot price | 11.08 |
|||
| Supports | First : | 9.18 |
Second : | 7.64 |
| MAs | MA(5) : | 9.78 |
MA(20) : | 11.24 |
| MA(100) : | 9.43  |
MA(250) : | 6.61 |
|
| MACD | MACD : | -0.4 |
Signal : | 0 |
| %K %D | K(14,3) : | 6.3 |
D(3) : | 15.1 |
| RSI | RSI(14): 24.2 |
|||
| 52-week | High : | 12.22 | Low : | 2.61 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ XGN ] has closed above bottom band by 3.1%. Bollinger Bands are 172.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.45 - 9.53 | 9.53 - 9.58 |
| Low: | 9.03 - 9.12 | 9.12 - 9.17 |
| Close: | 9.11 - 9.24 | 9.24 - 9.33 |
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Tue, 11 Nov 2025
Exagen Inc. to Participate in Fourth Quarter Investor Conferences - The Manila Times
Tue, 11 Nov 2025
Exagen (NASDAQ: XGN) to participate Nov 18–20 at Craig-Hallum and Canaccord conferences - Stock Titan
Mon, 10 Nov 2025
Exagen (XGN) Gets a Boost: BTIG Raises Price Target | XGN Stock News - GuruFocus
Mon, 10 Nov 2025
BTIG Maintains Exagen (XGN) Buy Recommendation - Nasdaq
Fri, 07 Nov 2025
Earnings Update: Here's Why Analysts Just Lifted Their Exagen Inc. (NASDAQ:XGN) Price Target To US$14.43 - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 22 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 15 (%) |
| Held by Institutions | 60.8 (%) |
| Shares Short | 790 (K) |
| Shares Short P.Month | 659 (K) |
| EPS | -0.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.95 |
| Profit Margin | -28.9 % |
| Operating Margin | -15.3 % |
| Return on Assets (ttm) | -16.3 % |
| Return on Equity (ttm) | -88 % |
| Qtrly Rev. Growth | 14.1 % |
| Gross Profit (p.s.) | 1.59 |
| Sales Per Share | 2.67 |
| EBITDA (p.s.) | -0.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -10.36 |
| PEG Ratio | 0 |
| Price to Book value | 9.6 |
| Price to Sales | 3.44 |
| Price to Cash Flow | -13.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|